Embla Medical hf.
EMBLA
Rank in Stocks
#6358
Embla Medical hf., together with its subsidiaries, provides non-invasive... Embla Medical hf., together with its subsidiaries, provides non-invasive orthopedic products in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It operates through three segments: Prosthetics and Neuro Orthotics, Bracing and Supports, and Patient Care. The Prosthetics and Neuro Orthotics segment offers mechanical products, such as lower and upper limb loss or difference; and bionic products, such as microprocessor-controlled feet, knees, hands, fingers, and neuro orthotic joints. The Bracing and Supports segment provides osteoarthritis solutions that are designed to reduce pain and improve mobility for people living with osteoarthritis; and injury solutions for people recovering from fractures, ligament injuries, or need post-operative treatment. This segment also offers Unloader One, a range knee braces that relieve pain from knee osteoarthritis; and Unloader Hip, which is designed to reduce pain by optimizing load dispersion for patients suffering from mild and moderate osteoarthritis of the hip. The Patient Care segment provides prosthetics for people with lower and upper limb loss or limb difference; and orthotics for neurological, gait, and musculoskeletal conditions. The company serves orthopedic and prosthetic clinics, hospitals, and surgery centers. It sells its products through its direct sales networks and distributors. The company was formerly known as Γssur hf. and changed its name to Embla Medical hf. in April 2024. Embla Medical hf. was incorporated in 1971 and is headquartered in Reykjavik, Iceland. Embla Medical hf. is a subsidiary of William Demant Invest A/S.
Share Price
$4.14
Last synced: 2026-11-12
Market Cap
$1.76B
Change (1 day)
-1.38%
Change (1 year)
-21.78%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Embla Medical hf. (EMBLA)
Category
Healthcare
Operating Margin for Embla Medical hf. (EMBLA)
Operating Margin as of November 2026 TTM: 14.03%
According to Embla Medical hf.'s latest financial reports, its current operating margin (TTM) is 14.03%. At the end of 2025 the company had an operating margin of 13.43%.
Operating Margin history for Embla Medical hf. from 2013 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 14.03% | 4.47% |
| 2025 | 13.43% | 1.82% |
| 2024 | 13.19% | 18.51% |
| 2023 | 11.13% | -6.08% |
| 2022 | 11.85% | -10.97% |
| 2021 | 13.31% | 54.95% |
| 2020 | 8.59% | -44.29% |
| 2019 | 15.42% | 13.80% |
| 2018 | 13.55% | -4.24% |
| 2017 | 14.15% | -3.81% |
| 2016 | 14.71% | -8.01% |
| 2015 | 15.99% | -5.05% |
| 2014 | 16.84% | 22.74% |
| 2013 | 13.72% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.00% | -98.93% |
US
|
|
| 18.08% | -98.71% |
IE
|
|
| 21.25% | -98.49% |
US
|
|
| 21.05% | -98.50% |
US
|
|
| 25.52% | -98.18% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Embla Medical hf.'s operating margin
What is Embla Medical hf.'s operating margin?
Embla Medical hf.'s operating margin is 14.03%, as of Nov 2026.
What was Embla Medical hf.'s operating margin in 2025?
In 2025, Embla Medical hf.'s operating margin was 13.43%, compared with 13.19% in 2024.
How has Embla Medical hf.'s operating margin changed since 2020?
From 2020 to 2025, Embla Medical hf.'s operating margin was highest in 2025 (13.43%) and lowest in 2020 (8.59%).
How does Embla Medical hf.'s operating margin compare with similar companies?
Embla Medical hf.'s operating margin (14.03%) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 25.52%.